SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1 (b) (c), AND (d)
Provectus Pharmaceuticals, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.001 par value
--------------------------------------------------------------------------------
(Title of Class of Securities)
74373-F-100
--------------------------------------------------------------------------------
(CUSIP Number)
February 14, 2006
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
|_| Rule 13d-1(b)
|X| Rule 13d-1(c)
|_| Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
CUSIP No. 74373-F-100 13G/A
--------------------------------------------------------------------------------
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Richard Smithline
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [_]
(b) [X]
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
5. SOLE VOTING POWER
3,772,176
-----------------------------------------------------------------
NUMBER OF 6. SHARED VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY -----------------------------------------------------------------
EACH 7. SOLE DISPOSITIVE POWER
REPORTING
PERSON 3,772,176
WITH -----------------------------------------------------------------
8. SHARED DISPOSITIVE POWER
0
--------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,772,176
--------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[_]
--------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.99%*
--------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON*
IN
--------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP No. 74373-F-100 13G/A
--------------------------------------------------------------------------------
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Centrecourt Asset Management LLC**
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [_]
(b) [X]
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
5. SOLE VOTING POWER
3,659,676
-----------------------------------------------------------------
NUMBER OF 6. SHARED VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY -----------------------------------------------------------------
EACH 7. SOLE DISPOSITIVE POWER
REPORTING
PERSON 3,659,676
WITH -----------------------------------------------------------------
8. SHARED DISPOSITIVE POWER
0
--------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,659,676
--------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[_]
--------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.99%*
--------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON*
OO
--------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP No. 74373-F-100 13G/A
--------------------------------------------------------------------------------
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
CAM Opportunity Advisors LLC**
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [_]
(b) [X]
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
5. SOLE VOTING POWER
0
-----------------------------------------------------------------
NUMBER OF 6. SHARED VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY -----------------------------------------------------------------
EACH 7. SOLE DISPOSITIVE POWER
REPORTING
PERSON 0
WITH -----------------------------------------------------------------
8. SHARED DISPOSITIVE POWER
0
--------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0
--------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[_]
--------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0
--------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON*
OO
--------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP No. 74373-F-100 13G/A
--------------------------------------------------------------------------------
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
CAMOFI Master LDC
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [_]
(b) [X]
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
--------------------------------------------------------------------------------
5. SOLE VOTING POWER
3,093,010
-----------------------------------------------------------------
NUMBER OF 6. SHARED VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY -----------------------------------------------------------------
EACH 7. SOLE DISPOSITIVE POWER
REPORTING
PERSON 3,093,010
WITH -----------------------------------------------------------------
8. SHARED DISPOSITIVE POWER
0
--------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,093,010
--------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[_]
--------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.99%*
--------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON*
OO
--------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
Item 1.
(a) Name of Issuer.
Provectus Pharmaceuticals, Inc.
(b) Address of Issuer's Principal Executive Offices.
7327 Oak Ridge Hwy., Suite A
Knoxville, TN 37931
Item 2.
(a) Name of Person Filing.
This Schedule 13G/A is being filed with respect to shares of Common
Stock of the Issuer which are beneficially owned by Richard
Smithline ("Mr. Smithline"), Centrecourt Asset Management LLC
("Centrecourt") and CAMOFI Master LDC ("CAMOFI") (collectively, the
"Reporting Persons").
The Reporting Persons are making a joint filing because they may be
deemed a group pursuant to Section 13 of the Securities Exchange Act
of 1934. The Reporting Persons do not affirm the existence of such a
group.
**Effective January 1, 2006, CAM Opportunity Advisors LLC was merged
with and into Centrecourt Asset Management LLC.
(b) Address of Principal Business Office or, if none, Residence.
The principal business address of each of Mr. Smithline and
Centrecourt is:
350 Madison Avenue, 8th Floor
New York, NY 10017
The principal business address of CAMOFI is:
90 Fort Street, 5th Floor
Box 32021 SMB
Grand Cayman, Cayman Islands
(c) Citizenship.
Mr. Smithline is a United States citizen.
Centrecourt is organized and existing in Delaware.
CAMOFI is organized and existing in the Cayman Islands.
(d) Title of Class of Securities.
Common Stock, $0.001 par value per share
(e) CUSIP Number.
74373-F-100
Item 3. If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c),
check whether the person filing is a:
(a) |_| Broker or dealer registered under Section 15 of the Act.
(b) |_| Bank as defined in Section 3(a)(6) of the Act.
(c) |_| Insurance Company as defined in Section 3(a)(19) of the Act.
(d) |_| Investment Company registered under Section 8 of the Investment
Company Act.
(e) |_| Investment Adviser in accordance with Sec.
240.13d-1(b)(1)(ii)(E).
(f) |_| Employee Benefit Plan or Endowment Fund in accordance with Sec.
240.13d-1(b)(1)(ii)(F).
(g) |_| Parent holding company, in accordance with Sec.
240.13d-1(b)(ii)(G).
(h) |_| A savings association as defined in Section 3(b) of the Federal
Deposit Insurance Act.
(i) |_| A church plan that is excluded from the definition of an
investment company under Section 3(c)(14) of the Investment
Company Act of 1940.
(j) |_| Group, in accordance with Sec. 240.13d-1(b)(1)(ii)(J).
If this statement is filed pursuant to Sec. 240.13d-1(c),
check this box |X|.
Item 4. Ownership
(a) Amount Beneficially Owned.
Mr. Smithline: 3,772,176 (comprised of
112,500 shares of Common Stock underlying
Warrants, 959,677 shares of Common Stock
held by CAMOFI, of which Mr. Smithline is a
director, 800,000 shares of Common Stock,
underlying Convertible Debentures held by
CAMOFI, of which Mr. Smithline is a
director, 1,333,333 shares of Common Stock
underlying Warrants held by CAMOFI, of which
Mr. Smithline is a director, and 566,666
shares of Common Stock underlying Warrants
held by Centrecourt, of which Mr. Smithline
is the Managing Member).
Centrecourt: 3,659,676 (comprised of 959,677
shares of Common Stock held by CAMOFI, of
which Centrecourt is the investment manager,
800,000 shares of Common Stock underlying
Convertible Debentures held by CAMOFI, of
which Centrecourt is the investment manager,
1,333,333 shares of Common Stock underlying
Warrants held by CAMOFI, of which
Centrecourt is the investment manager and
566,666 shares of Common Stock underlying
Warrants held by Centrecourt).
CAMOFI: 3,093,010 (comprised of 959,677
shares of Common Stock, 800,000 shares of
Common Stock, underlying Convertible
Debentures and 1,333,333 shares of Common
Stock underlying Warrants).
(b) Percent of Class. Mr. Smithline: 9.99%*
Centrecourt: 9.99%*
CAMOFI: 9.99%*
*Pursuant to the terms of the Convertible
Debentures and the Warrant Agreements,
Provectus Pharmaceuticals, Inc. has agreed
that the number of shares of Common Stock
that may be acquired by the holder of the
Debentures or Warrants upon any conversion
thereof (or otherwise in respect thereof)
shall be limited to the extent necessary to
insure that, following such conversion (or
other issuance), the total number of shares
of Common Stock then beneficially owned by
such holder does not exceed 9.99% of the
total number of issued and outstanding
shares of Common Stock. If not for the 9.99%
restriction described above, the ownership
percentages held by Mr. Smithline,
Centrecourt and CAMOFI would be 17.20%,
16.77%, and 14.55%, respectively.
(c) Number of shares as to which each such person has
(i) sole power to vote or to direct the vote:
Mr. Smithline: 3,772,176
Centrecourt: 3,659,676
CAMOFI: 3,093,010
(ii) shared power to vote or to direct the vote:
Mr. Smithline: 0
Centrecourt: 0
CAMOFI: 0
(iii) sole power to dispose or to direct the disposition of:
Mr. Smithline: 3,772,176
Centrecourt: 3,659,676
CAMOFI: 3,093,010
(iv) shared power to dispose or to direct the disposition of:
Mr. Smithline: 0
Centrecourt: 0
CAMOFI: 0
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more
than five percent of the class of securities, check the following |_|
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company or Control
Person.
See Item 4(a) above, which is incorporated by reference herein.
Item 8. Identification and Classification of Members of the Group.
The Reporting Persons may be deemed to constitute a group with one another
pursuant to Section 13 of the Securities Exchange Act of 1934. The
Reporting Persons do not affirm the existence of such a group.
Item 9. Notice of Dissolution of Group.
Not applicable.
Item 10. Certifications.
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were not acquired and are not held for
the purpose of or with the effect of changing or influencing the control
of the issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having that purpose
or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: February 3, 2006
/s/ Richard Smithline
--------------------------------
Richard Smithline
Centrecourt Asset Management LLC
By: /s/ Richard Smithline
----------------------------
Name: Richard Smithline
Title: Managing Member
CAMOFI Master LDC
By: /s/ Richard Smithline
----------------------------
Name: Richard Smithline
Title: Director
Attention: Intentional misstatements or omissions of fact constitute Federal
criminal violations (see 18 U.S.C. 1001).
EXHIBIT A
AGREEMENT
JOINT FILING OF SCHEDULE 13G/A
The undersigned hereby agree jointly to prepare and file with regulatory
authorities a Schedule 13G/A and any amendments thereto reporting each of the
undersigned's ownership of securities of Provectus Pharmaceuticals, Inc. and
hereby affirm that such Schedule 13G/A is being filed on behalf of each of the
undersigned.
Date: February 3, 2006
/s/ Richard Smithline
--------------------------------
Richard Smithline
Centrecourt Asset Management LLC
By: /s/ Richard Smithline
----------------------------
Name: Richard Smithline
Title: Managing Member
CAMOFI Master LDC
By: /s/ Richard Smithline
----------------------------
Name: Richard Smithline
Title: Director